The Blue Swan cover art

The Blue Swan

The Blue Swan

Written by: Sean Adler
Listen for free

In a landscape where innovation is a contact sport, The Blue Swan Podcast explores the science—and art—of thriving on the frontier. Hosted by Sean Adler—a visionary fitness leader, AI entrepreneur, and technical ninja with a sense of humor—whose journey spans the worlds of enterprise AI, bioinformatics, advanced calisthenics, and global media. His work and performances have been featured in Forbes, Fast Company, LA Fashion Week, and beyond. The Blue Swan is about more than just the pecking order. It’s about dancing on the razor’s edge of AI and entertainment, where quantitative rigor meets performance art, and the lines between data, movement, and storytelling are constantly redrawn. Through candid conversations with industry leaders, tech founders, athletes, and creative minds, The Blue Swan dives into what drives high-stakes performance—whether building agentic AI systems, pulling Hollywood stunts, optimizing risk, or biohacking. From regulatory navigation and portfolio optimization to martial arts, meditation, and the science of habit formation, you’ll hear stories and strategies you can use—no matter your arena. New episodes blend expert insight, creative exploration, and a dose of humor—because in business and life, adaptability is the ultimate edge. Sean's AI coaching apps are featured alongside Oscar, Grammy, and Tony award winners on Studio: https://studio.com/sean

seantzu.substack.comSean Adler Art Entertainment & Performing Arts
Episodes
  • Tal David and Amit Ben Kish: The Singularity is Here in Parallels with Quantum Art

    Tal David and Amit Ben Kish: The Singularity is Here in Parallels with Quantum Art
    May 15 2026
    The Quantum Revolution: A Paradigm Shift for AI SynergyTal David and Amit Ben Kish, founders of Quantum Art, describe quantum computing not merely as an upgrade to existing software, but as a fundamental hardware paradigm shift. While AI remains a software revolution running on traditional CPUs and GPUs, quantum computing utilizes Quantum Processing Units (QPUs) to solve problems with a completely different logic. Tal highlights three massive implications of this technology: accelerating specific AI workloads by factors of a million or more, drastically reducing energy consumption compared to current AI data centers, and creating a “two-way street” where AI helps design more complex quantum systems. Amit emphasizes that their trapped-ion architecture allows for exponential memory and computational space, enabling calculations—such as complex chemical reactions—that are physically impossible for classical computers to store or process. The company is focused on the intense capital and engineering effort required to integrate optics, vacuum systems, and quantum physics into a commercially viable product.Ions and Multi-Qubit Gates: A Quantum MosaicQuantum Art’s technical strategy centers on the use of trapped ions, which Amit describes as “nature’s perfect qubits.” Unlike superconducting modalities that require cooling entire massive fridges to near absolute zero, Quantum Art uses lasers to cool only the ions themselves, significantly increasing efficiency. To overcome the inherent noise in quantum systems, the team employs a “logical qubit” approach, bunching physical qubits together to fix errors faster than they occur. Their unique architecture utilizes multi-qubit gates—“beasts” capable of performing thousands of operations in a single step—and a reconfigurable “Quantum FPGA” design that allows them to compress complex circuits into a tiny physical footprint.The Advantage of Quantum-AI Symbiosis: 2027 and BeyondTal outlines two critical milestones for the industry: the “Quantum Advantage” moment and “Utility Scale.” Quantum advantage—the point where a quantum computer surpasses the world’s most powerful supercomputers on commercially relevant problems—is expected as early as late 2027 or 2028. This requires roughly 50 to 100 noiseless, logical qubits. The broader utility scale, involving systems with a million qubits capable of unlocking the technology’s full potential, is projected for the mid-next decade. Hybrid quantum-classical AI data centers are expected to consume orders of magnitude less energy than today’s AI data centers. Tal notes that this shift could eliminate the need for energy-intensive solutions like nuclear-powered data centers, making quantum computing a cornerstone of sustainable technology. While the hardware will likely remain in data centers rather than iPhones, Tal notes that “Quantum as a Service” already allows users to access this power via the cloud.Lights, Camera, Quantum: From Drug Discovery to Digital ArtThe versatility of quantum computing allows mathematical solutions in one field to migrate seamlessly to others. Tal explains how solving the wave equation for telecommunications—analyzing signal propagation through buildings—can be mapped directly onto computer animation to simulate ocean waves with extreme precision. The technology is poised to disrupt pharma through high-complexity molecular modeling, finance through fraud detection, and logistics through traffic optimization. By using sophisticated compilers and transpilers, Quantum Art aims to make this transition invisible to the end-user, providing a software-like experience backed by quantum hardware.Building a World-Class Infrastructure on a Nobel FoundationThe genesis of Quantum Art is rooted in elite academia and deep-tech experience. Amit reflects on his time working at NIST Boulder with Nobel laureate Dave Wineland, whose “Bible” of quantum processes laid the groundwork for the industry twenty-five years ago. Spun out of the Weizmann Institute in 2022, Quantum Art has rapidly scaled to a team of over 60 specialists from institutions like Stanford and Harvard, as well as industry giants like Intel and Google. The New York Stock Exchange foreshadowed their future with an honorable mention after raising a record-breaking $140 million Series A.Testing the Waters: The Temperature is RightTal concludes that quantum computing is no longer science fiction; it is an approaching reality that requires a “paradigm shift” in organizational thinking. He notes that most Fortune 500 companies are already “testing the temperature” by developing applications today. His advice to technological organizations is direct: “get your hands dirty” by using simulators and working with hardware providers now to prepare for the imminent quantum revolution. Get full access to Seantzu at seantzu.substack.com/subscribe
    Show More Show Less
    38 mins
  • Edwin Mata: Diamonds are a Token's Best Friend but Royalties are Forever

    Edwin Mata: Diamonds are a Token's Best Friend but Royalties are Forever
    Apr 30 2026
    Revolutionizing Asset Tokenization: Simplicity, Speed, and StructureEdwin Mata demystifies tokenization as the process of transforming real-world assets—such as real estate, equities, intellectual property, and luxury goods—into digital tokens that can be divided, distributed, and settled on a blockchain. Brickken’s platform streamlines the traditionally complex and bureaucratic world of securitization, enabling capital formation with unprecedented speed and efficiency. Crucially, Edwin emphasizes that tokenization is not a regulatory loophole; it is an efficiency layer that operates strictly within existing legal frameworks. “If something is not legal to be securitized or offered to the public, then it won’t be tokenized,” he asserts. Brickken’s technology accelerates compliant processes, offering features like T+0 settlement and one-click dividend distribution.The Power of Intangible Assets: IP, Royalties, and EntertainmentBrickken’s mission extends beyond tangible assets to the world of intangibles—intellectual property, royalties, music licensing, film rights, and event access. Edwin explains how tokenization empowers creators—musicians, filmmakers, and artists—to monetize their work and unlock new revenue streams, all while maintaining control and compliance. He highlights the challenges of navigating complex legal frameworks, such as sync licensing in music or FIFA’s strict IP rules for athletes. Brickken’s adaptable technology ensures that each asset’s unique legal structure is respected, empowering creators without overstepping regulatory boundaries.Bridging the Gap Between Technology and RegulationCompliance is at the heart of Brickken’s approach. Edwin details how the platform integrates Know Your Customer (KYC) protocols and accreditation checks to ensure offerings meet local securities laws. In the U.S., Brickken’s system enforces regulatory guardrails—blocking non-accredited investors and tailoring processes to frameworks like Regulation D. In Europe, the platform aligns with MiFID II and adapts to country-specific requirements. “We format the technology for you to be compliant under the regulation that you’re trying to enact,” Edwin explains, positioning Brickken as both an innovation engine and a compliance backbone.Tokenization Across All Asset Classes: From Diamond Rings to Biotech StartupsBrickken is redefining investor access to a diverse array of asset classes—from Picasso paintings and diamond rings to biotech startups and film productions. Tokenization democratizes access to previously illiquid markets, allowing investors to participate in short-term, high-yield opportunities once reserved for institutions. Edwin notes, however, that investor appetite often favors short-duration, high-liquidity, high-yield instruments—a reflection of Web3’s culture of instant liquidity. Successfully blending these expectations with the realities of real-world assets requires careful calibration and robust corporate governance, ensuring legal authority is established before tokenization proceeds.Valuation, Trust, and the Role of Certified PartnersTrust and transparency are central to Brickken’s model. The platform offers best-practice valuation guidance and connects issuers with certified valuation partners worldwide. These assessments can be embedded directly into smart contracts, creating a verifiable trust link between an asset’s value and what investors purchase. This is especially vital for early-stage or independent issuers who may lack established financial histories. While Brickken is not an auditor, its network of partners ensures credibility and rigor for every offering.The Derivatives Dilemma: Why Real-World Assets Are Not Digital-NativeEdwin addresses the complexities of creating derivatives for tokenized real-world assets. Unlike digital assets or commodities with real-time valuation and deep liquidity, real-world assets—like art or private equity—lack 24/7 valuation infrastructure. Attempting to create derivatives in such markets risks generating “fake markets” and destabilizing early participants. Edwin cautions against treating real-world assets as digital-native, emphasizing the need for robust market makers, liquidity providers, and real-time data before derivatives can safely flourish in this space.The Future of Tokenized Ecosystems: AI, Real-Time Valuation, and Mass DigitizationLooking forward, Edwin envisions artificial intelligence as a game-changer for real-time asset valuation. AI agents could continuously scan financial data and provide live valuation signals, unlocking the full potential of tokenized ecosystems. However, he warns that continuous information flow is a double-edged sword—real-time exposure could destabilize smaller companies not ready for public scrutiny. The goal is to balance transparency and efficiency with the stability needed for early-stage issuers to thrive.A Vision for the Future: The Great ...
    Show More Show Less
    27 mins
  • Eze Abosi: Backed by Novartis to Feed Your Head with AI Drug Development

    Eze Abosi: Backed by Novartis to Feed Your Head with AI Drug Development
    Apr 24 2026
    Visionary Leadership in Life SciencesEze Abosi is a trailblazer in the life sciences industry, leveraging over 20 years of expertise in healthcare, data analytics, and consulting to reshape how clinical and genomic data are utilized to improve patient care. As the Chief Growth Officer at Holmusk, a Series B-stage medical technology company backed by Novartis, Abosi leads sales, marketing, and service functions, driving the company’s mission to redefine neuropsychiatry and neuroscience research. Under his leadership, Holmusk has become a critical player in the integration of clinical and genomic data, empowering researchers, healthcare providers, and biopharma companies to address the most complex challenges in healthcare.Psychedelics: A New Dimension in Mental HealthAbosi and Holmusk are at the cutting edge of psychedelic drug development, a burgeoning field that promises to revolutionize the treatment of mental health disorders. As the U.S. FDA and other global regulators begin to fast-track the approval of psychedelic therapies, Holmusk plays a critical role by providing enriched datasets that help biotech companies like Compass Pathways and Atai Life Sciences advance their clinical trials.Abosi highlights the transformative potential of psychedelics, such as psilocybin and MDMA, in treating mental health conditions like depression and anxiety. With a focus on data enrichment, Holmusk supports these organizations by creating high-quality evidence to showcase the efficacy and safety of psychedelic therapies. “The lack of significant side effects in psychedelics, compared to traditional treatments like benzodiazepines, makes them a game-changer for patients,” Abosi explains. Holmusk is also helping to bridge the gap between hallucinogenic properties and therapeutic benefits by supporting research into second-generation psychedelics that isolate medicinal properties while minimizing hallucinogenic effects.AI Drug Development: Accelerating Discovery with DataArtificial intelligence in drug development is one of the most exciting and challenging frontiers in healthcare, and Abosi is positioning Holmusk at its forefront. By integrating high-quality, curated clinical data with cutting-edge machine learning techniques, Holmusk enables biopharma companies to de-risk the critical early stages of drug discovery and clinical research.Abosi explains that Holmusk’s datasets are particularly valuable for AI applications that aim to characterize patient populations and identify underserved subgroups. This capability is especially relevant in central nervous system (CNS) disorders, where Holmusk’s enriched datasets allow researchers to stratify patients by symptoms and develop therapies targeted at specific subpopulations, such as acute anxiety or treatment-resistant depression.Despite the potential of AI in drug development, Abosi notes that progress has been relatively slow, often stalling at Phase 2 trials. However, Holmusk is working to change that by fostering collaborations with researchers and biotech firms to accelerate the application of AI in clinical trials and commercialization. “AI is only as good as the data it’s applied to,” Abosi says. “Our role is to ensure that the data is robust, enriched, and capable of driving breakthroughs in drug development.”Pioneering the Intersection of Physical and Mental HealthOne of Holmusk’s most groundbreaking achievements lies in its ability to link physical and mental health outcomes through data. Abosi points to collaborations with institutions like Oxford University and Stanford’s Bioinformatics Department as examples of how Holmusk is breaking down silos in healthcare.A notable study conducted in partnership with Oxford explored correlations between GLP-1 medications (commonly used for cardiometabolic conditions) and mental health outcomes. Holmusk’s enriched datasets revealed meaningful insights into how these medications not only improve physical health but also impact cognitive function and mental health disorders like anxiety and depression. “This research represents the holy grail of healthcare,” Abosi says. “By looking at the patient holistically, we can establish critical links between physical and brain health.”The Skinny on GLP-1: Redefining Drug Market AccessBeyond research and development, Abosi is driving innovation in how drugs are commercialized and accessed. Holmusk collaborates with payers, pharma companies, and healthcare providers to create robust economic stories for new therapies. This is particularly critical in CNS disorders, where traditional approaches to drug development and commercialization often fall short.For example, Holmusk helps manufacturers demonstrate the economic value of their therapies by showing how premium-priced medications can reduce overall healthcare costs. Abosi provides the example of GLP-1 medications: although more expensive than generics like Metformin, GLP-1s have been shown to ...
    Show More Show Less
    29 mins
adbl_web_anon_alc_button_suppression_c
No reviews yet